Skip to main content
Premium Trial:

Request an Annual Quote

Lophius Joins Germany-funded Effort to Develop MS Dx

NEW YORK (GenomeWeb News) – Lophius Biosciences today said that it has joined a research consortium that will work with the firm on developing its T-Track MS diagnostic test for initial diagnosis of multiples sclerosis and monitoring of disease progression.

The project is part of the NEU2 program and has received funding of €350,000 ($468,800) from Germany's Federal Ministry of Education and Research.

Lophius is developing a T-cell-based diagnostic test kit for MS, which it believes will fill an unmet clinical need by offering a rapid blood-based test for differential diagnosis of the disease. The test is based on the firm's Reverse T Cell Technology platform, which "exploits the maturation processes induced in antigen presenting cells via a specific interaction with activated T helper cells thus representing an indirect measure for activated Th cells," the firm said in a statement.

"Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track MS test kit and help Lophius to initiate a broader clinical discovery and development program," Michael Lutz and Ralf Wagner, managing directors of Regensburg, Germany-based Lophius Biosciences, said.

The NEU2 program was created to initiate collaborations between academic institutions, biotech, and pharmaceutical companies in Germany. It is coordinated by Bionamics and has a particular focus on developing therapeutics for multiple sclerosis.

Earlier this year Lophius raised $5.3 million in a private financing round.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.